Zai Lab markets three products in the Greater China region:

ZEJULA® (niraparib)

ZEJULA is an oral, once-daily small-molecule poly ADP-ribose polymerase (PARP) 1/2 inhibitor. It is the only once-daily PARP inhibitor approved in mainland China as a monotherapy maintenance treatment for patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of their biomarker status. Zai Lab licensed ZEJULA for Greater China from Tesaro, now part of GlaxoSmithKline.

Optune®/Tumor Treating Fields

Optune is a wearable, portable device approved by the NMPA for the treatment of patients with newly diagnosed glioblastoma (GBM) in combination with temozolomide, and also as a monotherapy for the treatment of patients with recurrent GBM. Optune works by creating Tumor Treating Fields, which are electric fields tuned to specific frequencies to disrupt cell division. Zai Lab licensed Optune/Tumor Treating Fields for Greater China from Novocure.

QINLOCK® (ripretinib)

QINLOCK is a switch-control tyrosine kinase inhibitor engineered to broadly inhibit KIT- and PDGFRα-mutated kinases. It is the only therapeutic approved in China for advanced gastrointestinal stromal tumors (GIST) patients who have received prior treatment with three or more kinase inhibitors in the all-comer setting. Zai Lab licensed Optune/Tumor Treating Fields for Greater China from Deciphera Pharmaceuticals.


Adagrasib is a highly selective and potent oral small-molecule inhibitor of KRASG12C for treating KRAS-G12C-mutated non-small-cell lung cancer, colorectal cancer, pancreatic cancer and other solid tumors. Zai Lab licensed adagrasib for Greater China from Mirati Therapeutics.


Bemarituzumab is a first-in-class antibody that is being developed in gastric and gastroesophageal junction cancer as a targeted therapy for tumors that overexpress FGFR2b. Zai Lab licensed bemarituzumab for Greater China from Five Prime Therapeutics, now part of Amgen.


CLN-081 is an orally available, small-molecule, next-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertions. Zai Lab licensed CLN-081 for Greater China from Cullinan Oncology.


Efgartigimod is an antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process. Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Zai Lab licensed efgartigimod for Greater China from argenx.

MARGENZA™ (Margetuximab)

MARGENZA is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). Zai Lab licensed margetuximab for Greater China from MacroGenics.

NUZYRA® (omadacycline)

NUZYRA is a once-daily oral and intravenous antibiotic for the treatment of adults with CABP and ABSSSI. Zai Lab licensed omadacycline for Greater China from Paratek Pharmaceuticals.


Odronextamab is a bispecific monoclonal antibody designed to trigger tumor killing by linking and activating a cytotoxic T-cell (binding to CD3) to a lymphoma cell (binding to CD20). Zai Lab licensed odronextamab for Greater China from Regeneron Pharmaceuticals.


Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and TRK A/B/C, with the potential to treat TKI-naïve or TKI-pretreated patients. Zai Lab licensed repotrectinib for Greater China from Turning Point Therapeutics.

Simurosertib, ZL-2309 (CDC7)

Simurosertib, or ZL-2309, is a potential first-in-class oral selective inhibitor of CDC7, a protein kinase with key roles in DNA replication and in bypassing DNA damage response. Zai Lab owns global rights to simurosertib.

Sulbactam-Durlobactam (SUL-DUR)

Sulbactam-Durlobactam is a beta-lactam/beta-lactamase inhibitor combination that provides unique activity against Acinetobacter organisms, including carbapenem-resistant strains. Zai Lab licensed sulbactam-durlobactam for Greater China from Entasis Therapeutics.


Tebotelimab is an investigational, first-in-class, bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. Zai Lab licensed tebotelimab for Greater China from MacroGenics.


TPX-0022 is an orally bioavailable, multi-targeted kinase inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases. Zai Lab licensed TPX-0022 for Greater China from Turning Point Therapeutics.

ZL-1102 (IL-17 Nanobody)

ZL-1102 is a novel human nanobody targeting IL-17 with high affinity and avidity. Unlike other anti-IL-17 products, ZL-1102 is being developed as a topical treatment for chronic plaque psoriasis. Zai Lab owns global rights to ZL-1102.

ZL-1201 (CD47)

ZL-1201 is a humanized, IgG4 monoclonal antibody, engineered to reduce effector function, that specifically targets CD47. Its therapeutic potential will be assessed in both solid tumors and hematological malignancies and in both monotherapy and combination opportunities. Zai Lab owns global rights to ZL-1201.

Zai Lab has its headquarters and R&D operations in Shanghai, manufacturing and R&D operations in Suzhou, clinical and regulatory operations in Beijing, commercial operations in Guangzhou, Hong Kong, and Taiwan, R&D and business development operations in the San Francisco Bay area, and business operations in Cambridge, Massachusetts.

Zai Lab currently has about 1,600 employees worldwide.